- Pembrolizumab is well tolerated in patients with programmed death ligand 1 (PD-L1)-positive advanced recurrent ovarian cancer.
- The overall response rate was 11.5%; nearly 27% of patients had stable disease.
Why this matters
- Advanced ovarian cancer has a poor prognosis.
- Encouraging findings call for further investigation.
- Multicenter phase 1B KEYNOTE-028 study of 26 patients (median age, 57.5 years) with PD-L1-positive advanced ovarian epithelial, fallopian tube, or primary peritoneal carcinoma who failed previous therapy.
- 38.5% had metastatic disease; 73.1% previously received ≥3 lines of therapy.
- Patients received pembrolizumab (10 mg/kg every 2 weeks) for ≤24 months or until disease progression/intolerable toxicity.
- Funding: MSD.
- Median follow-up duration, 15.4 months.
- 73.1% of patients experienced treatment-related adverse events (TRAEs); the most common were arthralgia (19.2%), nausea (15.4%), pruritus (15.4%), diarrhea (11.5%), and rash (11.5%).
- 1 grade ≥3 TRAE (increased plasma transaminase level) was reported.
- The overall response rate was 11.5% (1 complete response, 2 partial responses), and 26.9% of patients achieved stable disease.
- Median PFS was 1.9 (95% CI, 1.8-3.5) months, and OS was 13.8 (95% CI, 6.7-18.8) months, respectively.
- Open-label design.